Ruxolitinib’s place in the future treatment landscape for MPNs

(1:43)

Phase I study of ruxolitinib plus abemaciclib for patients with myelofibrosis

(1:1econd)

Advantages and limitations of ruxolitinib for cGvHD

(4:12)

Management of ruxolitinib failure in myelofibrosis

(2:10)

Pros and cons of ruxolitinib for the treatment of MPNs

(3:40)

Novel combinations with ruxolitinib being investigated for myelofibrosis

(2:55)

The impact of early ruxolitinib treatment on OS in the COMFORT-I and COMFORT-II studies

(1:20)

The efficacy of ruxolitinib re-treatment in patients with MF

(1:41)

The ongoing use of ruxolitinib in myelofibrosis

(1:58)

Real-world use of ruxolitinib in patients with myelofibrosis with anemia or thrombocytopenia

(2:7)

Treating with ruxolitinib

(1:49)

Ongoing clinical trials of ruxolitinib-based combinations in myelofibrosis

(5:12)

Ruxolitinib combinations in patients with myelofibrosis

(2:14)

Ruxolitinib in the real world: myelofibrosis

(2:54)

The characteristics of patients with myelofibrosis taking ruxolitinib for 3 or more years

(1:38)

Pacritinib vs Ruxolitinib

(1:11)

Benefits of pelabresib with ruxolitinib for treatment naïve myelofibrosis

(2:41)

Panobinostat plus ruxolitinib in myelofibrosis

(1:32)

MANIFEST: ruxolitinib plus pelabresib for JAK-inhibitor naïve myelofibrosis

(3:21)

Reviewing the role and efficacy of ruxolitinib in myelofibrosis ten years after its approval

(1:15)